胸腺上皮性肿瘤中TTF1、Ki-67的表达与WHO分型的关系及临床意义

doi:10.11904/j.issn.1002-3070.2016.03.007

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (3): 229-234.doi: 10.11904/j.issn.1002-3070.2016.03.007

胸腺上皮性肿瘤中TTF1、Ki-67的表达与WHO分型的关系及临床意义

孙也淇¹, 陈鹏²

1.南华大学附属第一医院病理科(衡阳 421001);
2.南华大学药物药理研究所

收稿日期:2015-03-19 出版日期:2016-06-20 发布日期:2016-07-01
通讯作者: 陈鹏,E-mail:liuliuqiqime@163.com
作者简介:孙也淇,女,(1986-),硕士研究生,从事纵膈肿瘤的研究

Expression and clinical significance of TTF1 and Ki-67 in thymic epithelial tumors associated with World Health Organization classification

SUN Yeqi¹,CHEN Peng²

1.Department of Pathology,The First Affiliated Hospital of University of South China,Hengyang 421001,China;
2.Institute of Pharmacy and Pharmacology,University of South China

Received:2015-03-19 Online:2016-06-20 Published:2016-07-01

摘要/Abstract

摘要： 目的观察TTF1及Ki-67在胸腺上皮性肿瘤(Thymic epithelial tumors,TET)中的表达情况,探讨其与WHO分型的关系及二者的相关性。方法收集59例TET标本,其中诊断一致的51例,不一致8例。应用免疫组化技术检测TTF1及Ki-67在诊断一致的 51例TET及30例胸腺增生组织中的表达情况,并分析其与临床病理参数之间的关系。结果在诊断不一致的8例TET中,4例与AB型有关。在诊断一致的51例TET中,TTF1及Ki-67在TET中的表达均显著高于胸腺增生组(P＜0.05)。TTF1仅在AB型胸腺瘤中表达(11/15),其表达与WHO分型有关。Ki-67标记指数从A型到胸腺癌逐渐增加,且在A型与胸腺癌的表达范围不重叠,其表达与WHO分型及MasaoKa分期均有关。同时TTF1及Ki-67在TET中的表达没有相关性。结论 TTF1是AB型胸腺瘤相对特异性的标记;Ki-67不仅对A型与胸腺癌中的区分有帮助,同时具有很好的指示预后的价值。

关键词: TTF1, Ki-67, TET, WHO分型, MasaoKa分期

Abstract: Objective To study the role of TTF1 and Ki-67 in thymic epithelial tumors(TET)and their relevance.Methods Fifty-nine cases of TET were collected.The pathologists were agreed on 51 cases,disagreed 8 cases,4 of which were involved with type AB.Immunohistochemistry was used to detect TTF1 and Ki-67 expressions in 51 TET with unanimous diagnosis and 30 thymic hyperplasia tissues.The correlations of TTF1 and Ki-67 expression in TET and clinical pathologic characteristics were statistically analyzed.Results Among the disagreed cases,4 of 8 were involved with type AB.There were significant differences of TTF1 and Ki-67 expressions between hyperplasia tissues and TET.Only 11 of 15 type AB expressed TTF1.The expression of TTF1 had positive correlation with World Health Organization classification(WHO)in TET.Ki-67 labeling index increased from type A to thymic carcinoma and its expression range of type A and thymic carcinoma did not overlap each.Ki-67 labeling index was correlated with WHO and clinical stages in TET.Furthermore,the expression of TTF1 had no correlation with Ki-67 in TET.Conclusion TTF1 is a highly specific marker for type AB.Ki-67 is useful for distinguishing type A from thymic carcinoma and guiding treatment by predictive value.

Key words: TTF1, Ki-67, TET, WHO classification, MasaoKa stage

中图分类号:

736.3

孙也淇, 陈鹏. 胸腺上皮性肿瘤中TTF1、Ki-67的表达与WHO分型的关系及临床意义[J]. 实用肿瘤学杂志, 2016, 30(3): 229-234.

SUN Yeqi,CHEN Peng. Expression and clinical significance of TTF1 and Ki-67 in thymic epithelial tumors associated with World Health Organization classification[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 229-234.

参考文献

1 de Jong WK,Blaauwgeers JL,Schaapveld M,et al.Thymic epithelial tumors:a population based study of the incidence,diagnostic procedure and therapy[J].Eur J Cancer,2008,44(1):123-130.
2 Hosaka Y,Tsuchida M,Toyabe S,et al.Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma[J].Ann Thorac Surg,2010,89(3):912-917.
3 Anja C.Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas[J].Hum Pathol,2015,46:17-25.
4 宋楠,姜格宁.胸腺瘤的分类进展[J].中国胸心外科临床杂志,2009,16(2):132-136.
5 Venuta F,Anile M,Diso D,et al.Thymoma and thymic carcinoma[J].Eur J Cardiothorac Surg,2012,60(1):1-12.
6 Suster S.Dignostic of the thymoma[J].J Clin Pathol,2006,59(12):1238-1244.
7 Marx A,Strbel P,Badve SS,et al.ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma:refined definitions,histological criteria,and reporting[J].J Thorac Oncol,2014,9(5)596-611.
8 Kazuza K,Kiyoshi Y,Masaru T,et al.WHO histologic classification is a prognostic indicator in the thymoma[J].Ann Thorac Surg,2004,77(4):1183-1188.
9 Okummra M,Ohta M,Tateyama H,et al.The World Health Organization histological classification system reflects the oncologic behavior of thymoma:a clinical study of 273 patients[J].Cancer,2002,94(3):624-632.
10 Oknmura M,Miyoshi S,Fujii Y,et al.Clinical and functional significance of WHO classification on human thymic epithelial neoplasms:a study of 146 consecutive tumors[J].Am J Surg Pathol,2001,25(1):103-110.
11 Rieker RJ,Hoegel J,Morresi-Hauf A,et al.Histologic classification of thymic epithelial tumors:comparison of established classification schemes[J].Int J Cancer,2002,98(6):900-906.
12 Marchevsky AM,Gupta R,McKenna RJ,et al.Evidence-based pathology and the pathologic evaluation of thymomas:the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma[J].Cancer,2008,112(12):2780-2788.
13 Matoso A,Singh K,Jacob R,et al.Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors[J].Appl Immunohistochem Mol Morphol,2010,18(2):142-149.
14 Yan B,Seng SC,Petersson F.Thymoma with nuclear expression of thyroid transcription factor-1:a potential diagnostic pitfall on core biopsy[J].Appl Immunohistochem Mol Morphol,2011,19(1):76-81.
15 Pomplun S,Wotherspoon AC,Shah G,et al.Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms[J].Histopathology,2002,40(2):152-158.
16 Smith T,Mauri F,Naresh KN.Thyroid transcription factor-1 immunostaining in World Health Organization type AB thymoma[J].Histopathology,2016,68(4):618-619.
17 Pan CC,Chen PC,Chou TY,et al.Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma[J].Hum Pathol,2003,34(11):1155-1162.
18 Weissferdt A,Carlos-Hernandez J,Kalhor N,et al.Spindle cell thymomas:an immunohistochemical study of 30 cases[J].Appl Immunohistochem Mol Morphol,2011,19(4):329-335.
19 Wyllie AH.The biology of cell death in tumours[J].Anticancer Res,1985,5(1):131-136.
20 蔡彦力,黄杰,黄进启.PTEN,表皮生长因子受体和Ki-67在胸腺瘤中的表达及其临床意义[J].中国胸心血管外科临床杂志,2005,15(2):108-112.
21 Hiroshima K,Lyode A,Toyozaki T,et al.Proliferative activity and apoptosis in thymic epithelial neoplasms[J].Mod Pathol,2002,15(7):1326-1332.

[1]	王佳娜, 沈建军, 张艳红, 王佳天, 李文秀, 潘军英. Ki-67及PTEN在口腔腺样囊性癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(6): 489-493.
[2]	刘冰梅, 杨晶, 张翰文, 邢荣贵, 李丽丽, 赵丽萍, 乔适, 尤海燕. 角化棘皮瘤与高分化鳞状细胞癌细胞周期和细胞凋亡相关蛋白表达的研究[J]. 实用肿瘤学杂志, 2014, 28(6): 485-491.
[3]	樊秋兰, 董晓秋, 邵小慧, 王璐璐, 张立维. 乳腺癌超声特征与Ki-67表达的相关性[J]. 实用肿瘤学杂志, 2013, 27(1): 65-68.
[4]	王鹏, 张艳枝, 石穆穆, 李淑芝, 李玉荣, 朱辉. 我国北方汉族女性乳腺癌中PELP1/MNAR表达特征及其与Ki-67标记指数相关性研究[J]. 实用肿瘤学杂志, 2012, 26(5): 452-457.
[5]	滕冲, 宋晓薇, 蔡莉. Ki-67在乳腺癌新辅助化疗中的作用及临床意义[J]. 实用肿瘤学杂志, 2012, 26(2): 188-192.
[6]	李爽, 陈元. Mina53、Ki-67在中国人大肠癌中的表达及其与临床病理学之间的关系[J]. 实用肿瘤学杂志, 2011, 25(6): 537-543.
[7]	杨萌, 娄阁. AEG-1与Ki-67在上皮性卵巢组织中的表达及其临床病理相关性的研究[J]. 实用肿瘤学杂志, 2011, 25(5): 411-415.
[8]	刘扬, 庞达. 乳腺癌新辅助化疗前后Ki-67、HER-2、ER和PR的变化与临床缓解率的关系[J]. 实用肿瘤学杂志, 2011, 25(5): 442-445.
[9]	韩晓峰, 李月锋, 曲宏岩. Pokemon、Ki-67蛋白在胃癌中的表达和临床意义[J]. 实用肿瘤学杂志, 2011, 25(3): 219-222.
[10]	王艳, 刘杰, 白淑平, 李乐静, 冯军, 王晓红, 王梅, 刘静蕾. VEGF、Ki-67和P53在非小细胞肺癌组织中的表达及意义[J]. 实用肿瘤学杂志, 2011, 25(3): 238-241.
[11]	逯仁波, 王小川, 马荣, 耿晓星. 宫颈癌组织中ADAM-19、Ki-67的表达及临床意义^△[J]. 实用肿瘤学杂志, 2011, 25(2): 114-119.
[12]	吕丽艳, 韩波, 关景明, 赵春波. Survivin、Ki-67和COX-2在结直肠腺瘤旁鸡皮样黏膜中的表达及意义[J]. 实用肿瘤学杂志, 2010, 24(5): 422-424.
[13]	林镇和, 陈炬莹, 陈晓耕. p53、Ki-67、TopoⅡ、GST、P170对三阴乳腺癌预后的相关性分析[J]. 实用肿瘤学杂志, 2010, 24(2): 138-143.
[14]	于丽娟, 田墨涵, 梁秀艳, 刘蕊, 段钰, 王文志. 肺癌CT征象与Ki-67、Survivin及CyclinA表达的关系^△[J]. 实用肿瘤学杂志, 2009, 23(6): 524-527.
[15]	蔡会龙, 刘扬, 黄孙卉, 杨悦, 庞达, 姬宏飞. 乳腺浸润性导管癌组织Ki-67和p53蛋白的表达及其临床意义^△[J]. 实用肿瘤学杂志, 2009, 23(6): 531-534.

胸腺上皮性肿瘤中TTF1、Ki-67的表达与WHO分型的关系及临床意义

Expression and clinical significance of TTF1 and Ki-67 in thymic epithelial tumors associated with World Health Organization classification

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价